Comparison of baseline test results and subsequent diagnosis in the follow-up period 2 (n=4043)
| Worst histology diagnosis n (%) | |||||
| CIN2+ n=64 | CIN3+ n=40 | No histological abnormality n=576 | No histology n=3403 | Total n=4043 | |
| Baseline | |||||
| Cytology alone | |||||
| ASCUS+ | 30 (46.9) | 19 (47.5) | 95 (16.5) | 29 (0.9) | 154 (3.8) |
| ASCUS | 7 (10.9) | 5 (12.5) | 54 (9.4) | 25 (0.7) | 86 (2.1) |
| LSIL | 5 (7.8) | 4 (10.0) | 14 (2.4) | 3 (0.1) | 22 (0.5) |
| HSIL+* | 18 (28.1) | 10 (25.0) | 27 (4.7) | 1 (0.0) | 46 (1.1) |
| Cytology/HPV triage | |||||
| Positive† | 27 (42.2) | 18 (45.0) | 49 (8.5) | 3 (0.1) | 79 (2.0) |
| HPV alone | |||||
| HPV 16/18 | 18 (28.1) | 14 (35.0) | 57 (9.9) | 9 (0.3) | 84 (2.1) |
| HrHPV other | 35 (54.7) | 22 (55.0) | 103 (17.9) | 102 (3.0) | 240 (5.9) |
| HPV/cytology triage | |||||
| Positive‡ | 35 (54.7) | 27 (67.5) | 75 (13.0) | 10 (0.3) | 120 (3.0) |
Percentages are per column.
*HSIL+ included HSIL, AGC, adenoCIS, ASCH, and malignant cells from cervical cancer.
†positive includes referrals to colposcopy: HSIL+, and ASCUS/LSIL with concurrent positive hrHPV test result (all hr-types).
‡positive includes referrals to colposcopy: all HPV 16/18 positive and hrHPV other types positive with concurrent ASCUS+.